Quantum-Si (NASDAQ:QSI) CEO Sells $10,179.90 in Stock

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,311 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $0.90, for a total value of $10,179.90. Following the transaction, the chief executive officer owned 3,669,802 shares of the company’s stock, valued at approximately $3,302,821.80. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Monday, June 22nd, Jeffrey Alan Hawkins sold 11,310 shares of Quantum-Si stock. The stock was sold at an average price of $0.96, for a total transaction of $10,857.60.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The stock was sold at an average price of $1.01, for a total transaction of $84,549.12.

Quantum-Si Price Performance

QSI opened at $0.85 on Friday. Quantum-Si Incorporated has a 12-month low of $0.69 and a 12-month high of $3.10. The stock has a market capitalization of $186.14 million, a PE ratio of -1.68 and a beta of 3.18. The firm’s fifty day moving average price is $0.99 and its 200 day moving average price is $1.03.

Quantum-Si (NASDAQ:QSI) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. On average, equities research analysts forecast that Quantum-Si Incorporated will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on QSI. Canaccord Genuity Group lowered their price objective on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum-Si in a report on Wednesday. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Quantum-Si currently has an average rating of “Reduce” and an average price target of $1.00.

Institutional Trading of Quantum-Si

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Quantum-Si by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after purchasing an additional 9,005 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Quantum-Si by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,082 shares of the company’s stock valued at $96,000 after buying an additional 10,564 shares during the period. Prudential Financial Inc. acquired a new position in shares of Quantum-Si in the 2nd quarter valued at about $25,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Quantum-Si by 23.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock valued at $85,000 after buying an additional 13,546 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Quantum-Si during the 2nd quarter valued at about $29,000. Institutional investors own 39.90% of the company’s stock.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.